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Abstract
Background Sodium oxybate has been recognized as a gold standard for the treatment of disrupted nighttime sleep due to
narcolepsy. Its short half-life and immediate-release formulation require patients to awaken 2.5–4 h after their bedtime dose
to take a second dose. A novel extended-release, once-nightly sodium oxybate formulation (ON-SXB; FT218) is under US
Food and Drug Administration review for the treatment of adults with narcolepsy.
Objective A phase III trial of ON-SXB in individuals with narcolepsy type 1 (NT1) or 2 (NT2) [the REST-ON trial;
NCT02720744] has been conducted and the primary results reported elsewhere. Secondary objectives from REST-ON were
to assess the efficacy of ON-SXB on disrupted nighttime sleep; the results of this analysis are reported here.
Methods In the double-blind, phase III REST-ON trial, patients aged ≥ 16 years were randomly assigned 1:1 to ON-SXB
(1 week, 4.5 g; 2 weeks, 6 g; 5 weeks, 7.5 g; 5 weeks, 9 g) or placebo. Secondary endpoints included polysomnographic
measures of sleep stage shifts and nocturnal arousals and patient-reported assessments of sleep quality and refreshing nature
of sleep at 6, 7.5, and 9 g; post hoc analyses included changes in time spent in each sleep stage, delta power, and assessments
in stimulant-use subgroups for prespecified endpoints.
Results In total, 190 participants (n = 97, ON-SXB; n = 93, placebo) were included in the efficacy analyses. All three ONSXB doses demonstrated a clinically meaningful, statistically significant decrease vs placebo in the number of transitions to
wake/N1 from N1, N2, and rapid eye movement (REM) stages (all doses p < 0.001) and the number of nocturnal arousals
(p < 0.05 ON-SXB 6 g; p < 0.001 7.5 and 9 g). Sleep quality and refreshing nature of sleep were significantly improved
with all three ON-SXB doses vs placebo (p < 0.001). Post hoc analyses revealed a significant reduction in time spent in
N1 (p < 0.05 ON-SXB 6 g; p < 0.001 7.5 and 9 g) and REM (all p < 0.001) and increased time spent in N3 with ON-SXB
vs placebo (all p < 0.001), with a significant increase in delta power (p < 0.01 ON-SXB 6 g; p < 0.05 7.5 g; p < 0.001 9 g)
and increased REM latency (ON-SXB 7.5 g vs placebo; p < 0.05). Significant improvements in disrupted nighttime sleep
were observed regardless of concomitant stimulant use.
Conclusions The clinically beneficial, single nighttime dose of ON-SXB significantly improved disrupted nighttime sleep
in patients with narcolepsy.
Clinical Trial Registration ClinicalTrials.gov NCT02720744.

1 Introduction
At the time the study was conducted, Dr. Jordan Dubow’s
affiliation was Clinical Development and Medical Affairs, Avadel
Pharmaceuticals, 16640 Chesterfield Grove Road, Suite 200,
Chesterfield, MO 63005, USA
* David Seiden
Dseiden@avadel.com
Extended author information available on the last page of the article

Narcolepsy is a chronic sleep disorder affecting approximately 1 out of every 2000 individuals [1, 2]. Narcolepsy
is characterized by a pentad of symptoms, including excessive daytime sleepiness (EDS), cataplexy, disrupted nighttime sleep (DNS; also known as disturbed nocturnal sleep),
sleep paralysis (SP), and hypnagogic/hypnopompic hallucinations [1, 3]. Although DNS is universally seen as a narcolepsy disease-related symptom, a wide range of prevalence
Vol.:(0123456789)
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Key Points
One of the most frequently reported symptoms of narcolepsy is disturbed nocturnal sleep/disrupted nighttime
sleep, characterized by a disruption in sleep architecture
and sleep continuity. FT218 is an investigational, novel,
once-nightly formulation of sodium oxybate.
In this randomized controlled clinical trial, both subjective and objective measures of disrupted nighttime sleep
were significantly improved for the once-nightly formulation of sodium oxybate at 6, 7.5, and 9 g vs placebo.
The results from this trial support the use of a oncenightly formulation of sodium oxybate for the nocturnal
symptoms of narcolepsy, as well as an improvement in
patients’ perception of their sleep, including in those
taking concomitant stimulants and/or wake-promoting
agents.

estimates is reported (~ 30–95%) [4]. Numerous factors
such as the presence of rapid eye movement (REM) sleep
behavior disorder, nightmares, periodic limb movements of
sleep, obstructive sleep apnea, depression, anxiety, hallucinations, sleep paralysis, and obesity contribute to DNS
[4–7]. Furthermore, varying definitions of DNS in narcolepsy are employed in both the literature and clinical practice, contributing to the wide range of DNS prevalence rates
[4, 8]. A recently validated 15-item self-administered questionnaire, the Narcolepsy Severity Scale, includes an item to
assess the presence and frequency of DNS [8]. In a study of
patients with narcolepsy type 1 (NT1) that used the Narcolepsy Severity Scale, DNS was reported to be the third most
frequent symptom (95.5% of untreated patients with three
symptoms), exceeded only by EDS and cataplexy. Despite
its high prevalence, it is unclear whether clinicians routinely
assess or monitor this symptom. Additionally, sleep fragmentation is a frequent finding in polysomnographic (PSG)
recordings in individuals with narcolepsy. Less time in slowwave sleep (SWS), frequent awakenings/arousals, more N1
sleep, and more frequent awakenings from deeper stages of
sleep are consistently found on PSG recordings in patients
with narcolepsy [4].
Sodium oxybate (SXB), the sodium salt of
ɣ-hydroxybutyrate, has been recognized as the gold standard for disrupted sleep due to narcolepsy [9]. However,
the immediate-release formulations require the patients
to awaken for the second dose 2.5–4 h after the first dose
owing to the short half-life of ɣ-hydroxybutyrate (i.e., 30–60
min) [10, 11]. This required awakening disrupts sleep continuity. Results describing improvements in DNS with
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immediate-release SXB have been published; however, the
data are presented as bifurcated segments of sleep [12]. This
bifurcation and disruption of sleep highlights an unmet medical need in the treatment of nighttime symptoms in patients
with narcolepsy.
FT218 is an investigational, extended-release, oncenightly formulation of SXB (ON-SXB). In a randomized,
open-label, crossover pilot study evaluating the pharmacokinetic properties of ON-SXB, a single 6-g dose was shown to
be bioequivalent in drug exposure (i.e., area under the curve)
to two 3-g doses of immediate-release SXB administered
4 h apart [13]. In the 13-week, phase III, REST-ON clinical
trial (NCT02720744) of patients with narcolepsy, all three
evaluated doses of ON-SXB (6, 7.5, and 9 g) were effective
on all three coprimary endpoints and demonstrated clinically meaningful and statistically significant improvements
compared with placebo in EDS as assessed by the Maintenance of Wakefulness Test, overall condition as measured by
Clinical Global Impression of Improvement, and frequency
of cataplexy attacks, all with p < 0.001 [14]. Significant
results were observed at week 3, the earliest formal assessment with the 6-g dose. In REST-ON, ON-SXB was generally well tolerated. Most adverse events were mild or moderate in severity and diminished over time. The most common
adverse reactions with ON-SXB were consistent with the
well-characterized safety profile of SXB and included vomiting, dizziness, and enuresis [10, 15].
Secondary endpoints of the REST-ON trial reported here
included both objective and subjective assessments of DNS
in patients with narcolepsy. These assessments include PSG
measures of sleep instability (i.e., shifts to wake or N1 from
N1, N2, N3, and REM) and nocturnal arousals (NAs), as
well as patient-reported assessments of both sleep quality
and refreshing nature of sleep.

2 Methods
2.1 Study Design
REST-ON was a multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial (NCT02720744). The
study design, which consisted of a 3-week screening period,
a 13-week treatment period, and a 1-week follow-up period,
was described previously [14]. The study was approved by
an institutional review board or independent ethics committee for each study center. REST-ON was performed in
accordance with the Declaration of Helsinki, Good Clinical
Practice guidelines, International Council for Harmonisation
guidelines, and any applicable regulatory requirements at
the local and national level. Written informed consent was
provided by all adult participants (≥ 18 years old). Young
adults (16 and 17 years old) must have been capable of

Improvement in Disrupted Nighttime Sleep with Once-Nightly Sodium Oxybate

giving assent followed by consent from a legally authorized
guardian.

2.2 Participants
Eligible participants were aged 16 years or older, with a
diagnosis of NT1 or narcolepsy type 2 (NT2) as defined by
the criteria listed in the International Classification of Sleep
Disorders, Third Edition [16]. Participants who previously
used SXB were excluded (except use of SXB ≤ 4.5 g for
≤ 2 weeks and ≥ 1 year before study entry), as were those
who had a diagnosis of sleep apnea (apnea-hypopnea index
≥ 15) or any other sleep disorder known to cause EDS as
determined by PSG findings and sleep history. Concomitant stimulant use was allowed (initiated ≥ 3 weeks before
starting the screening process and the same stimulant regimen continued throughout the entire study period). Detailed
participant inclusion/exclusion criteria can be found in the
primary REST-ON publication [14].

2.3 Treatment
Stratified randomization was performed based on the
presence of narcolepsy type (NT1 or NT2), with patients
assigned in a 1:1 ratio to treatment with ON-SXB or placebo. Doses of study medication were 4.5 g for 1 week, 6
g for 2 weeks, 7.5 g for 5 weeks, and 9 g for 5 weeks taken
once nightly at bedtime. The dosing paradigm was designed
this way to demonstrate the efficacy and safety of 6, 7.5 and
9 g of ON-SXB. All study personnel were blinded to the
study treatments, and a double-blind approach was used to
ensure the integrity of the study blinding.

2.4 Assessments
Secondary efficacy endpoints were change from baseline in
(1) frequency of sleep stage transitions, (2) NAs, and (3)
patient-reported quality of sleep and refreshing nature of
sleep. Overnight, in-clinic PSG was performed at baseline
and at weeks 3, 8, and 13. Stage transitions were assessed
as the number of shifts from N1 (light sleep), N2, N3 (deep
sleep), and REM sleep to wake and from N2, N3, and REM
sleep to N1. Nocturnal arousals were defined as the number of transient arousals on nocturnal PSG following the
American Academy of Sleep Medicine Scoring Guidelines
for PSG [17], i.e., an abrupt shift of electroencephalography
frequency including alpha, theta, and/or frequencies greater
than 16 Hz (but not spindles), greater than 3 s of changed
frequency on electroencephalography, at least 10 s of stable
sleep preceding the change, and in REM sleep, an increase
in submental electromyography for at least 1 second. Quality of sleep and refreshing nature of sleep were assessed
using a visual analog scale (VAS) and were recorded daily
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in an electronic sleep diary. The VAS ranged from 1 to 100,
with 1 indicating “did not sleep”/“not refreshed” and 100
indicating “slept very well”/“refreshed.” Post hoc analyses
included the amount of time spent in N1, N2, N3, and REM
sleep; REM latency; shifts from REM to wake/N1; and delta
power for non-REM sleep in the whole-night recording as an
objective measure of DNS and the assessment of prespecified endpoints associated with DNS (i.e., shifts, arousals,
sleep quality, and refreshing nature of sleep) in subgroups of
participants who were vs who were not taking concomitant
stimulants and/or wake-promoting medications.

2.5 Statistical Analyses
Efficacy analyses were based on the modified intent-to-treat
population, defined as all patients randomized to treatment
with at least one efficacy measurement after receiving either
the 6-g dose of ON-SXB or placebo. Least-squares mean
(LSM) differences vs placebo, associated 95% confidence
intervals (CIs), and p-values were calculated. LSM change
from baseline in the PSG and VAS measures were analyzed
using a mixed-effects model for repeated measures that
included treatment, time at which measurements were taken,
treatment-by-time interaction, site (USA or non-USA), and
baseline score as fixed effects, and subjects as random
effects. For stage shifts, the p-value was estimated using a
mixed-effects model for repeated measures with additional
criteria including change from baseline in the number of
wakefulness or N1 stages after sleep onset as the response
variable, covariate of baseline number of wakefulness or N1
stages after sleep onset, and unstructured variance-covariance structure. Mean VAS responses were averaged over the
14 days preceding the test day. Post hoc analyses included
changes from baseline in total time spent in N1, N2, N3, and
REM sleep; REM latency; and delta power. All statistical
tests were performed using a two-sided alpha test with a 5%
overall significance level, unless otherwise noted. Secondary efficacy endpoints did not take multiplicity into account.

3 Results
3.1 Patient Disposition and Demographics
Of the 413 candidates who were screened, 222 (53.8%) were
randomized 1:1 to ON-SXB or placebo (n = 111, each), and
212 of those randomized (95.5%) received one or more doses
of the study drug. Baseline demographics and clinical characteristics of all randomized patients in the REST-ON trial
were generally similar between treatment arms; full patient
demographics and disposition information have been previously published [14]. The majority of patients were female
(n = 144; 67.9%) and white (n = 160; 75.5%) with a mean
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Fig. 1  Change from baseline
in sleep stage shifts (modified
intent-to-treat population).
A mixed-effects model for
repeated measures was used
for analyses of sleep stage
shifts. Least-squares mean
(LSM) change from baseline in
sleep stage shifts for patients
receiving once-nightly sodium
oxybate (ON-SXB) or matching
placebo. CI confidence interval,
SD standard deviation, SE
standard error

age of 31.2 years (range, 16–72 years). Overall, 162 (76.4%)
participants had NT1 (ON-SXB, n = 80 [74.8%]; placebo, n
= 82 [78.1%]) and 50 (23.6%) had NT2 (ON-SXB, n = 27
[25.2%]; placebo, n = 23 [21.9%]). The modified intent-totreat population consisted of 190 (85.6%) participants; 145
(65.3%) participants had NT1 (ON-SXB, n = 73 [65.8%];
placebo, n = 72 [64.9%]).
Only one participant had prior SXB exposure (≤ 4.5 g for
≤ 2 weeks and ≥ 1 year before study entry). In total, 63% of
participants in the modified intent-to-treat population were
receiving concomitant stimulants. The most common concomitant stimulants were modafinil (ON-SXB, 21.5%; placebo, 21.0%), armodafinil (ON-SXB, 12.1%; placebo, 6.7%),
dextroamphetamine (ON-SXB, 9.3%; placebo, 7.6%), mixed
amphetamine salts (ON-SXB, 10.3%; placebo, 5.7%), lisdexamfetamine (ON-SXB, 4.7%; placebo, 5.7%), and methylphenidate (ON-SXB, 10.3%; placebo, 6.7%).

3.2 Efficacy
3.2.1 Stage Shifts
The number of stage shifts was similar between the ONSXB and placebo arms at baseline (60.1 and 60.3, respectively). The total number of transitions from sleep to wake
or N1 from N1, N2, N3, and REM was significantly reduced
with ON-SXB vs placebo at week 3 for the 6-g dose (LSM
change from baseline, − 9.7 vs 1.3; p < 0.001); at week 8
for the 7.5-g dose (− 15.0 vs 2.7, respectively; p < 0.001);
and at week 13 for the 9-g dose (– 20.5 vs 2.1, respectively;
p < 0.001) (all Fig. 1).

3.2.2 NAs
At baseline, the number of NAs was similar in the ON-SXB
and placebo arms (81.8 and 77.2, respectively). The LSM
change from baseline in the number of NAs was significantly
reduced with ON-SXB vs placebo at week 3 for the 6-g dose
(− 31.3 vs − 20.0, respectively; p < 0.05); at week 8 for the
7.5-g dose (− 39.26 vs − 19.8, respectively; p < 0.001); and
at week 13 for the 9-g dose (− 39.4 vs − 15.7, respectively;
p < 0.001) (all Fig. 2).
3.2.3 Sleep Quality
Patient-reported sleep quality was similar between the ONSXB and placebo arms at baseline (mean VAS score, 53.8
and 55.9). Patient-reported sleep quality was significantly
improved with ON-SXB vs placebo at week 3 for the 6-g
dose (LSM change from baseline, 11.9 vs 5.0, respectively;
p < 0.001); at week 8 for the 7.5-g dose (18.8 vs 9.0, respectively; p < 0.001); and at week 13 for the 9-g dose (21.4 vs
11.0, respectively; p < 0.001) (all Fig. 3).
3.2.4 Refreshing Nature of Sleep
Refreshing nature of sleep reported by participants at baseline was similar between the ON-SXB and placebo arms
(mean VAS score, 46.5 and 49.9, respectively). The LSM
change from baseline in patient-reported refreshing nature
of sleep was significantly increased with ON-SXB vs placebo at week 3 for the 6-g dose (13.0 vs 6.7, respectively;
p < 0.001); at week 8 for the 7.5-g dose (20.6 vs 9.3,
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Fig. 2  Change from baseline
in nocturnal arousals (modified intent-to-treat population). A mixed-effects model
for repeated measures was
used for analyses of nocturnal
arousals. Least-squares mean
(LSM) change from baseline in
nocturnal arousals for patients
receiving once-nightly sodium
oxybate (ON-SXB) or matching
placebo. CI confidence interval,
PSG polysomnography, SD
standard deviation, SE standard
error

Fig. 3  Change from baseline in
sleep quality (modified intentto-treat population). A mixedeffects model for repeated measures was used for sleep quality
analyses. Least-squares mean
(LSM) change from baseline in
patient-reported sleep quality
for patients receiving oncenightly sodium oxybate (ONSXB) or matching placebo. CI
confidence interval, SD standard
deviation, SE standard error,
VAS visual analog scale

respectively; p < 0.001); and at week 13 for the 9-g dose
(23.8 vs 12.4, respectively; p < 0.001) (all Fig. 4).
3.2.5 Post Hoc Analyses
A significantly reduced amount of time was spent in N1 with
ON-SXB vs placebo at week 3 for the 6-g dose (p < 0.05);
at week 8 for the 7.5-g dose (p < 0.001); and at week 13 for

the 9-g dose (p < 0.001) (all Table 1). No significant change
in time spent in N2 was observed at any dose of ON-SXB vs
placebo. A significantly increased amount of time was spent
in N3 with ON-SXB vs placebo at week 3 for the 6-g dose
(p < 0.001); at week 8 for the 7.5-g dose (p < 0.001); and at
week 13 for the 9-g dose (p < 0.001). A significant increase
in delta power for non-REM sleep occurred with all doses
of ON-SXB vs placebo (p < 0.01 ON-SXB 6 g [week 3];
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Fig. 4  Change from baseline
in refreshing nature of sleep
(modified intent-to-treat population). A mixed-effects model
for repeated measures was used
for refreshing nature of sleep
analyses. Least-squares mean
(LSM) change from baseline
in patient-reported refreshing
nature of sleep for patients
receiving once-nightly sodium
oxybate (ON-SXB) or matching placebo. CI confidence
interval, SD standard deviation,
SE standard error, VAS visual
analog scale

p < 0.05 ON-SXB 7.5 g [week 8]; p < 0.001 ON-SXB 9 g
[week 13]). The change from baseline in time in REM was
significantly reduced with ON-SXB vs placebo at week 3
for the 6-g dose (p < 0.001); at week 8 for the 7.5-g dose
(p < 0.001); and at week 13 for the 9-g dose (p < 0.001).
Rapid eye movement latency increased with ON-SXB at all
doses (range, 14.2–20.8 min) vs a decrease at all timepoints
with placebo (range − 2.4 to − 3.4 min; p < 0.05 ON-SXB
7.5 g [week 8] vs placebo); while not statistically significant
at week 3 (6-g dose) and week 13 (9-g dose), numerical
increases in REM latency were observed.
The efficacy of ON-SXB vs placebo was investigated in
the subgroups of participants who did or did not receive
concurrent stimulant treatment during the trial (Table 2).
The number of sleep shifts was significantly reduced with
ON-SXB vs placebo at all three doses in both the stimulant use subgroup (6 g, p < 0.01; 7.5 g, p < 0.001; 9 g,
p < 0.001) and the no stimulant use subgroup (all p < 0.001).
A significant reduction from baseline in NAs with ON-SXB
vs placebo was also observed with the 7.5-g and 9-g doses in
the stimulant use subgroup (p < 0.01 and p < 0.001, respectively) and at all doses in the no stimulant use subgroup (6 g
and 7.5 g, p < 0.05; 9 g, p ≤ 0.01). Significant improvements
in patient-reported sleep quality with ON-SXB vs placebo
were observed at all assessed doses in both the stimulant
use (6 g and 7.5 g, p < 0.01; 9 g, p < 0.05) and no stimulant
use (all p < 0.001) subgroups. Similarly, improvements in
patient-reported refreshing nature of sleep with ON-SXB
vs placebo were observed at all assessed doses in both the
stimulant use (6 g and 9 g, p < 0.05; 7.5 g, p < 0.001) and

no stimulant use subgroups (6 g and 7.5 g, p < 0.01; 9 g,
p < 0.001).

4 Discussion
The data reported in this paper expand our understanding of
the efficacy of ON-SXB for the treatment of the symptoms
of narcolepsy. These results demonstrate that ON-SXB is
associated with clinically significant improvements in sleep
continuity, sleep architecture, and patient satisfaction with
both the quality and refreshing nature of their sleep. Reductions in the number of transitions from sleep to wake and
deeper stages of sleep to light sleep with ON-SXB treatment vs placebo were statistically significant, and NAs were
also significantly reduced with ON-SXB treatment. Consistent with these improvements, a significant reduction in
the length of time spent in N1, a significant increase in the
time spent in N3, and increased delta power further support
ON-SXB positively affecting sleep in patients with narcolepsy. In further alignment with the clinical efficacy demonstrated by the REST-ON primary efficacy results [14],
significant improvements in patient-reported sleep quality
and refreshing nature of sleep with ON-SXB treatment
were reported. Overall, these significant findings provide
additional support for the efficacy of ON-SXB in patients
with narcolepsy. Moreover, they illustrate that for patients
with narcolepsy, pharmacotherapy can improve nocturnal
symptoms and patient perceptions of both sleep quality and
feeling refreshed after sleep.
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Table 1  Post hoc analysis: change from baseline in time spent in sleep stages, delta power, REM, and REM latency (modified intent-to-treat
population)
Parameter

Week 0
ON-SXB
n = 97

Week 3
Placebo
n = 93

N1 sleep
Time spent in N1 sleep at baseline, minutes
Mean (SD)
40.2 (22.1)
42.6 (21.2)
Change from baseline in N1, minutes
LSM (SE)
LSMD (95% CI)
N2 sleep
Time spent in N2 sleep at baseline, minutes
Mean (SD)
215.9 (52.2) 211.6 (48.3)
Change from baseline in N2, minutes
LSM (SE)
LSMD (95% CI)
N3 sleep
Time spent in N3 sleep at baseline, minutes
Mean (SD)
68.8 (31.5)
68.8 (28.1)
Change from baseline in N3, minutes
LSM (SE)
LSMD (95% CI)
Delta power in NREM
Baseline delta power in NREM
Mean (SD)
460.8 (336.8) 545.6 (656.5)
Change from baseline in delta power in NREM
LSM (SE)
LSMD (95% CI)
Total REM sleep
Total REM sleep at baseline, minutes
Mean (SD)
76.7 (30.8)
78.3 (27.7)
Change from baseline in total REM sleep, minutes
LSM (SE)
LSMD (95% CI)
REM latency
Baseline REM latency, minutes
Mean (SD)
69.1 (68.0)
56.0 (45.9)
Change from baseline in REM latency, minutes
LSM (SE)
LSMD (95% CI)

Week 8

Week 13

ON-SXB 7.5 g Placebo
n = 97
n = 93

ON-SXB 9 g
n = 97

− 6.2 (1.7)
− 0.3 (1.7)
− 5.9 (− 10.7 to − 1.1)*

− 10.3 (2.0)
0.73 (1.9)
− 11.0 (− 16.5 to − 5.5)***

− 13.2 (1.8)
0.15 (1.7)
− 13.4 (− 18.4 to − 8.4)***

– 8.5 (4.1)
− 1.9 (4.1)
− 6.6 (− 18.1 to 4.9)

2.7 (4.4)
− 1.0 (4.3)
3.6 (− 8.4 to 15.7)

− 11.5 (5.0)
2.0 (4.7)
− 13.5 (− 27.1 to 0.1)

27.6 (3.0)
5.5 (3.0)
22.1 (13.6–30.5)***

30.4 (3.7)
3.6 (3.6)
26.8 (16.6–37.0)***

39.5 (4.3)
1.1 (4.1)
38.4 (26.7–50.1)***

ON-SXB 6 g
n = 97

Placebo
n = 93

Placebo
n = 93

239.4 (62.4) − 6.5 (63.5) 400.3 (95.3)
90.2 (101.3) 640.8 (110.8)
67.2 (106.3)
245.8 (69.0–422.7)**
310.0 (33.3–586.7)*
573.6 (266.8–880.4)***

− 16.1 (2.6)
0.6 (2.6)
− 21.3 (2.7)
5.9 (2.7)
− 22.8 (3.3)
1.7 (3.1)
− 16.7 (− 23.9 to − 9.5)*** − 27.2 (− 34.8 to − 19.6)*** − 24.5 (− 33.4 to − 15.6)***

14.2 (6.8)
− 3.4 (6.8)
17.6 (− 1.4 to 36.6)

19.7 (7.6)
− 3.4 (7.5)
23.1 (2.0–44.2)*

20.8 (8.6)
− 2.4 (8.1)
23.2 (− 0.21 to 46.6)

Mixed-effects model for repeated measures used to assess significance at each timepoint
CI confidence interval, LSM least-squares mean, LSMD least-squares mean difference, NREM non-rapid eye movement, ON-SXB once-nightly
sodium oxybate, REM rapid eye movement, SD standard deviation, SE standard error
*p < 0.05; **p < 0.01; ***p < 0.001

A previous assessment of twice-nightly SXB also showed
increases in time spent in N3 and corresponding decreases
in N1 and REM sleep, whereas N2 remains unaffected [12];
however, these data are presented separated into the first and
the second half of the night owing to the need to awaken for

the second middle-of-the-night dose required to cover a full
night of sleep [10]. A required awakening for the second
dose 2.5–4 h after the first bedtime dose by definition is a
disruption of sleep. Although immediate-release SXB has
been shown to increase the overall amount of time spent in
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Table 2  Post hoc analysis: sleep stage shifts, NAs, sleep quality, and refreshing nature of sleep by stimulant use (modified intent-to-treat population)
Baseline
Parameter

ON-SXB

Sleep stage shifts
Stimulant use
n = 66
Baseline, mean 59.2 (24.5)
(SD)
LSM change
from baseline
(SE)
LSMD (95% CI)
No stimulant use n = 31
Baseline, mean 62.1 (21.0)
(SD)
LSM change
from baseline
(SE)
LSMD (95% CI)
NAs
Stimulant use
n = 66
Baseline, mean 78.5 (46.4)
(SD)
LSM change
from baseline
(SE)
LSMD (95% CI)
No stimulant use n = 31
Baseline, mean 89.0 (36.8)
(SD)
LSM change
from baseline
(SE)
LSMD (95% CI)
VAS sleep qualitya
Stimulant use
n = 66
Baseline, mean 54.7 (19.1)
(SD)
LSM change
from baseline
(SE)
LSMD (95% CI)
No stimulant use n = 31
Baseline, mean 51.8 (24.3)
(SD)
LSM change
from baseline
(SE)
LSMD (95% CI)
VAS refreshing nature of s leepa
Stimulant use
n = 66
Baseline, mean 49.0 (20.4)
(SD)

Week 3
Placebo

Week 8

Week 13

ON-SXB 6 g

Placebo

ON-SXB 7.5 g

Placebo

ON-SXB 9 g

Placebo

− 8.4 (2.2)

0.6 (2.4)

− 12.8 (3.0)

3.4 (3.1)

− 19.6 (2.6)

1.5 (2.6)

n = 53
64.0 (22.8)

n = 40
55.3 (19.5)

− 9.0 (− 15.5 to − 2.5)**

− 16.2 (− 24.8 to − 7.6)***

− 21.1 (− 28.5 to − 13.8)***

– 13.4 (2.8)

– 20.2 (3.6)

– 23.4 (4.1)

– 3.5 (2.5)

− 16.9 (– 24.5 to – 9.3)***

2.8 (3.2)

– 23.0 (– 32.8 to – 13.3)***

4.1 (3.6)

− 27.6 (– 38.4 to – 16.7)***

n = 53
76.4 (30.6)
– 26.6 (4.2)

n = 40
78.2 (46.7)

– 20.2 (4.5) – 35.8 (4.2)

– 6.4 (– 18.7 to 5.9)

– 40.2 (6.2)

– 17.1 (4.4) – 36.0 (4.6)

– 18.8 (– 30.8 to – 6.8)**

– 20.7 (5.5) – 45.6 (7.7)

– 14.7 (4.5)

– 21.3 (– 34.1 to – 8.5)***

– 23.5 (6.8) – 46.0 (8.2)

– 17.0 (7.2)

– 19.5 (– 36.0 to – 3.0)*

– 22.1 (– 42.6 to – 1.6)*

– 29.0 (– 50.8 to – 7.1)**

10.7 (1.3)

18.3 (1.6)

19.5 (1.9)

n = 53
55.5 (19.0)

n = 40
56.5 (27.0)

5.4 (1.6–9.1)**

14.7 (2.1)
10.2 (4.6–15.9)***
n = 53
50.9 (21.8)

5.4 (1.4)

10.9 (1.7)

7.4 (2.9–12.0)**

4.5 (1.8)

19.4 (2.8)
13.2 (5.7–20.8)***

13.0 (2.0)

6.5 (1.1–11.9)*

6.2 (2.5)

24.9 (3.2)

8.2 (2.8)

16.7 (8.1–25.3)***
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Table 2  (continued)
Baseline
Parameter

ON-SXB

Week 3
Placebo

LSM change
from baseline
(SE)
LSMD (95% CI)
No stimulant use
n = 31
n = 40
Baseline, mean 41.3 (24.1) 48.6 (25.3)
(SD)
LSM change
from baseline
(SE)
LSMD (95% CI)

Week 8

Week 13

ON-SXB 6 g

Placebo

ON-SXB 7.5 g

Placebo

ON-SXB 9 g

Placebo

11.5 (1.4)

7.0 (1.6)

20.5 (1.7)

11.7 (1.8)

22.6 (2.0)

15.1 (2.1)

4.5 (0.3–8.7)*

16.1 (2.4)

8.8 (3.9–13.6)***

6.4 (2.0)

9.7 (3.5–15.8)**

20.6 (3.4)

7.6 (1.8–13.3)*

6.1 (2.9)

14.5 (5.6–23.4)**

25.7 (3.8)

8.8 (3.2)

16.9 (7.0–26.8)***

Mixed-effects model for repeated measures used to assess significance at each timepoint
CI confidence interval, LSM least-squares mean, LSMD least-squares mean difference, NA nocturnal arousal, ON-SXB once-nightly sodium oxybate, REM rapid eye movement, SD standard deviation, SE standard error, VAS visual analog scale, *p < 0.05; **p ≤ 0.01; ***p < 0.001
a

VAS of 1–100, with 1 indicating “did not sleep”/“not refreshed” and 100 indicating “slept very well”/“refreshed”

SWS [12, 18, 19], the larger increase was observed in the
second half of the night [12], which is in contrast to when
SWS typically occurs following the homeostatic drive to
sleep after a period of wakefulness [20].
Slow-wave sleep is considered the deepest and most
restorative stage of sleep and is associated with sleep quality
and maintenance of sleep [20–23]. A recently completed systematic review and meta-analysis showed that SWS is diminished in people with narcolepsy compared with controls
(n = 65 studies) and similar in NT1 vs NT2 (n = 41 studies)
[24]. During SWS, there is a reduction in sympathetic activity; a reduction in this sleep stage may adversely affect blood
pressure and contribute to hypertension [25–27]. Whether
the increase in SWS with ON-SXB confers additional clinical benefits merits further research.
A significant reduction in overall REM sleep was demonstrated with all three ON-SXB doses, which was previously demonstrated with the 9-g dose of twice-nightly SXB
[12]. ON-SXB increased REM sleep latency at all doses
compared with placebo, which was statistically significant at
the 7.5-g dose. The clinical implications of SXB modifying
REM sleep are not entirely known, although nocturnal REM
suppression may theoretically decrease SP, hypnagogic/hypnopompic hallucinations, and vivid dreaming.
The magnitude of change in measures of DNS was greater
for participants who were not taking concomitant stimulants,
although no statistical comparisons were made between
groups given that these are post hoc analyses. Significant
improvements in sleep stage transitions, NAs, and patientreported sleep quality and refreshing nature of sleep were
observed with ON-SXB vs placebo regardless of concurrent
stimulant use. Polypharmacy may be necessary for patients
with narcolepsy, and many take stimulants for daytime

sleepiness [28, 29]. Thus, these findings provide reassuring
evidence that the efficacy of ON-SXB for the treatment of
DNS in narcolepsy will likely be maintained whether or not
the patients are using concurrent stimulants.
The analyses conducted in this trial have some limitations. Efficacy results presented are secondary endpoints,
not powered for a multiplicity analysis, and some were
conducted post hoc. However, improvements with ONSXB treatment were consistent over time and increased in
a dose-dependent manner, further substantiating the results
and decreasing the likelihood of a type 1 error.

5 Conclusions
The efficacy of a single bedtime dose of SXB was demonstrated for the treatment of DNS in participants with narcolepsy. Clinically relevant improvements were observed in
both objective measures (i.e., PSG-recorded decreases in
stage shifts and NAs) and subjective findings with participants reporting both improved quality and refreshing nature
of sleep. At all doses evaluated (6, 7.5, and 9 g), ON-SXB
treatment demonstrated a significant consolidation of nocturnal sleep, a significant improvement in time spent in deep
sleep, and a significant decrease in time spent in lighter sleep
vs placebo.
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